Spero Therapeutics, Inc.·4

Jun 25, 7:12 PM ET

VINK PATRICK V.J.J. 4

4 · Spero Therapeutics, Inc. · Filed Jun 25, 2026

Research Summary

AI-generated summary of this filing

Updated

Spero (SPRO) Director Patrick Vink Receives RSU and Option Awards

What Happened

  • Patrick V. J. J. Vink, a director of Spero Therapeutics (SPRO), was granted compensation awards on June 23, 2026: 10,000 restricted stock units (RSUs) and 20,000 derivative awards (option-related). Both grants were reported with an acquisition price of $0.00 (no cash paid at grant).

Key Details

  • Transaction date: 2026-06-23; Form 4 filed: 2026-06-25 (timely filing).
  • 10,000 RSUs (F1) — each RSU converts to one share on vesting; vesting date: June 23, 2027, subject to continued service.
  • 20,000 derivative/option-related award (F2) — the shares underlying this option will vest and become exercisable in full on June 23, 2027, subject to continued service.
  • Reported acquisition price: $0.00 for both awards (total cash paid at grant = $0).
  • Shares owned after the transaction: not specified in the provided filing excerpt.

Context

  • These transactions are grants/awards (compensation), not open-market purchases or sales — common for director compensation and do not represent an immediate market trade.
  • The RSUs convert to common stock only upon vesting; the derivative award/option becomes exercisable on the stated vesting date. No immediate sale or exercise was reported.

Insider Transaction Report

Form 4
Period: 2026-06-23
Transactions
  • Award

    Common Stock

    [F1]
    2026-06-23+10,00085,000 total
  • Award

    Stock Option (right to buy)

    [F2]
    2026-06-23+20,00020,000 total
    Exercise: $2.15Exp: 2036-06-23Common Stock (20,000 underlying)
Footnotes (2)
  • [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
  • [F2]The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Signature
/s/ Maegan Deare, Attorney-in-Fact for Patrick Vink|2026-06-25

Documents

1 file
  • 4
    ownership.xmlPrimary

    4